- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.05. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | Silexion reports breakthrough in KRAS-driven cancer therapy | 2 | Investing.com | ||
| 29.05. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | 174 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 21.05. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 21.05. | Silexion Therapeutics Corp: Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer | 154 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference... ► Artikel lesen | |
| 14.05. | Silexion Therapeutics GAAP EPS of $0.26 | 1 | Seeking Alpha | ||
| 13.05. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.05. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.05. | Silexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 97 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference... ► Artikel lesen | |
| 23.04. | Silexion Therapeutics Stock Surges 52% On Catalent Collaboration For Cancer Therapy | 1 | RTTNews | ||
| 23.04. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 23.04. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities | 7 | GlobeNewswire (USA) | ||
| 28.03. | Silexion erweitert Dual-Route-Strategie für KRAS-Krebstherapie | 1 | Investing.com Deutsch | ||
| 28.03. | Silexion advances dual-route strategy for KRAS cancer therapy | 2 | Investing.com | ||
| 28.03. | Silexion Therapeutics Corp: Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data | 159 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 28.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 18.03. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Silexion Therapeutics GAAP EPS of -$26.36 | 5 | Seeking Alpha | ||
| 18.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 1.011 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| PALATIN TECHNOLOGIES | 0,079 | -0,13 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| VERASTEM | 5,300 | -1,85 % | What's Going On With Verastem Oncology Stock On Monday? | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations... ► Artikel lesen | |
| QUANTUM-SI | 1,745 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,314 | -10,80 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial Results | CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 7,390 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,500 | 0,00 % | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
| MINK THERAPEUTICS | 6,980 | 0,00 % | MiNK Therapeutics receives NIH grant for GvHD therapy | ||
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,949 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.